Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 6/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 0.76 |
| ▸ | MAOB | P27338 | 3/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.76 |
| ▸ | ELANE | P08246 | 6/20 | 0.74 |
| ▸ | ACHE | P22303 | 3/20 | 0.69 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Z)-Aurone SCHEMBL305101 | 1.00 | STK17B (1.00) | STK17BMAOAMAOBHDAC3HDAC4 | |
| (Z)-Aurone SCHEMBL31266594 | 1.00 | STK17B (1.00) | STK17BMAOAMAOBHDAC3HDAC4 | |
| (Z)-Aurone SCHEMBL13971324 | 1.00 | STK17B (1.00) | STK17BMAOAMAOBHDAC3HDAC4 | |
| (Z)-Aurone SCHEMBL29935711 | 1.00 | STK17B (1.00) | STK17BMAOAMAOBHDAC3HDAC4 | |
| SCHEMBL19499394 | 0.94 | STK17B (0.89) | STK17BMAOAMAOBHDAC3HDAC4 | |
| SCHEMBL19462733 | 0.94 | STK17B (0.89) | STK17BMAOAMAOBHDAC3HDAC4 | |
| SCHEMBL19499403 | 0.90 | STK17B (0.81) | STK17BMAOAMAOBHDAC3HDAC4 | |
| SCHEMBL21082587 | 0.86 | STK17B (0.76) | STK17BMAOAMAOBHDAC3HDAC4 | |
| SCHEMBL21046410 | 0.86 | STK17B (0.76) | STK17BMAOAMAOBHDAC3HDAC4 | |
| SCHEMBL19462898 | 0.86 | MAOA (1.00) | STK17BMAOAMAOBHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059625-A | Mineral wool binder | 洛科威有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12614680-B1 | Dye-sensitized solar cell based on titanium dioxide, graphitic carbon nitride, and cadmium selenide nanocomposite | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-04-28 | — | — | US | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| CN-119462619-A | Orange ketone compound and medical application thereof | 浙江大学 | 2025-02-18 | — | — | CN | claimed |
| EP-4013725-B1 | MINERAL WOOL BINDER | ROCKWOOL AS (DK) | 2024-10-02 | — | — | EP | claimed |
| US-20240316118-A1 | ANTIVIRAL NASAL SPRAY FLAVONOIDS?BEE PROPOLIS | MCCAFFREY STEPHEN MARK (AU) | 2024-09-26 | — | — | US | claimed |
| CN-118356425-A | Semisynthetic aurone and its use method | 肯塔基大学研究基金会 | 2024-07-19 | — | — | CN | claimed |
| CN-118356427-A | Semisynthetic aurone and its use method | 肯塔基大学研究基金会 | 2024-07-19 | — | — | CN | claimed |
| CN-118063419-A | Orange ketoxime ester photoinitiator, preparation method and application thereof | 大连理工大学 | 2024-05-24 | — | — | CN | claimed |
| CN-116270345-B | Natural herbal cosmetic with effects of radiation protection, blood circulation activating, skin nourishing and anti-aging and application thereof | 北京娅熙妍国际贸易有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-1272140-A | Gene encoding protein having aurone synthesizing activity | SUNTORY LTD (JP) | 2000-11-01 | — | — | CN | claimed |
| EP-1001028-A1 | GENE ENCODING PROTEIN HAVING AURONE SYNTHESIZING ACTIVITY | SUNTORY LIMITED (JP) | 2000-05-17 | — | — | EP | claimed |
| WO-1997026873-A1 | ANTIMICROBIAL AURONE DERIVATIVES | PHYTERA, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| US-5603936-A | SOLVENT EXTRACTION | Ratcliff, Richard A. (US) | 1997-02-18 | — | — | US | claimed |
| EP-0528975-A4 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | — | 1993-09-15 | — | — | EP | claimed |
| EP-0528975-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1993-03-03 | — | — | EP | claimed |
| WO-1993001824-A1 | COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS | BAYLOR COLLEGE OF MEDICINE (US) | 1993-02-04 | — | — | WO | claimed |
| WO-1991017749-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1991-11-28 | — | — | WO | claimed |
| US-RE32196-E | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS | LILLY INDUSTRIES LIMITED (GB) | 1986-07-01 | — | — | US | claimed |
| US-4259340-A | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS SUCH AS ASTHMA | LILLY INDUSTRIES LIMITED (GB) | 1981-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12614680-B1 | Dye-sensitized solar cell based on titanium dioxide, graphitic carbon nitride, and cadmium selenide nanocomposite | SCN9A, CD2, CA9 | STK17B 2248/4885MAOA 2958/4885MAOB 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.